0000950170-24-041300.txt : 20240403
0000950170-24-041300.hdr.sgml : 20240403
20240403172300
ACCESSION NUMBER: 0000950170-24-041300
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240328
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Winton Matthew
CENTRAL INDEX KEY: 0001971400
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 24820157
MAIL ADDRESS:
STREET 1: C/O INOZYME PHARMA, INC.
STREET 2: 321 SUMMER STREET, SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
ownership.xml
4
X0508
4
2024-03-28
0001693011
Inozyme Pharma, Inc.
INZY
0001971400
Winton Matthew
C/O INOZYME PHARMA, INC.
321 SUMMER STREET SUITE 400
BOSTON
MA
02210
false
true
false
false
COO
false
Common Stock
2024-03-28
5
A
false
3188
3.33
A
3188
D
Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of October 1, 2023 through March 31, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on October 2, 2023, the first trading day of the purchase period.
/s/ Matthew Winton
2024-04-03